

**TDMS No.** 93020 - 03  
**Test Type:** 90-DAY  
**Route:** SKIN APPLICATION  
**Species/Strain:** RATS/F 344

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**  
DIISOPROPYLCARBODIIMIDE  
**CAS Number:** 693-13-0  
**Pathologist:** BIERLEY, B. - STEDHAM, M. - SHANAHAN, P.  
Final #2/Rats

**Date Report Requested:** 08/08/2005  
**Time Report Requested:** 08:53:32  
**First Dose M/F:** 09/06/94 / 09/07/94  
**Lab:** MBA

**C Number:** C93020  
**Lock Date:** 05/16/1995  
**Cage Range:** ALL  
**Date Range:** ALL  
**Reasons For Removal:** ALL  
**Removal Date Range:** ALL  
**Treatment Groups:** Include ALL

TDMS No. 93020 - 03  
 Test Type: 90-DAY  
 Route: SKIN APPLICATION  
 Species/Strain: RATS/F 344

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)  
 DIISOPROPYLCARBODIIMIDE  
 CAS Number: 693-13-0  
 Pathologist: BIERLEY, B. - STEDHAM, M. - SHANAHAN, P.

Date Report Requested: 08/08/2005  
 Time Report Requested: 08:53:32  
 First Dose M/F: 09/06/94 / 09/07/94  
 Lab: MBA

FISCHER 344 RATS MALE	0 MG/KG	10 MG/KG	20 MG/KG	40 MG/KG	80 MG/KG	160 MG/KG
<b>Disposition Summary</b>						
Animals Initially in Study	10	10	10	10	10	10
Early Deaths						
Moribund Sacrifice					10	3
Natural Death						7
Survivors						
Terminal Sacrifice	10	10	10	10		
Animals Examined Microscopically	10	10	10	10	10	10
<b>ALIMENTARY SYSTEM</b>						
Liver	(10)	(0)	(0)	(10)	(10)	(10)
Centrilobular, Congestion					4 (40%)	6 (60%)
Centrilobular, Vacuolization Cytoplasmic					1 (10%)	6 (60%)
Periportal, Vacuolization Cytoplasmic	1 (10%)					
Pancreas	(10)	(0)	(0)	(10)	(10)	(9)
Acinus, Atrophy, Focal	1 (10%)					
Stomach, Glandular	(10)	(0)	(0)	(10)	(10)	(10)
Infiltration Cellular, Mixed Cell				1 (10%)		
Cyst				1 (10%)		
<b>CARDIOVASCULAR SYSTEM</b>						
Heart	(10)	(10)	(10)	(10)	(10)	(10)
Cardiomyopathy	4 (40%)	4 (40%)	6 (60%)	4 (40%)	5 (50%)	3 (30%)
Artery, Inflammation, Chronic Active					1 (10%)	
<b>ENDOCRINE SYSTEM</b>						
None						
<b>GENERAL BODY SYSTEM</b>						
None						

TDMS No. 93020 - 03  
 Test Type: 90-DAY  
 Route: SKIN APPLICATION  
 Species/Strain: RATS/F 344

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)  
 DIISOPROPYLCARBODIIMIDE  
 CAS Number: 693-13-0  
 Pathologist: BIERLEY, B. - STEDHAM, M. - SHANAHAN, P.

Date Report Requested: 08/08/2005  
 Time Report Requested: 08:53:32  
 First Dose M/F: 09/06/94 / 09/07/94  
 Lab: MBA

FISCHER 344 RATS MALE	0 MG/KG	10 MG/KG	20 MG/KG	40 MG/KG	80 MG/KG	160 MG/KG
<b>GENITAL SYSTEM</b>						
Preputial Gland Inflammation, Chronic Active	(10) 2 (20%)	(0)	(0)	(10) 2 (20%)	(10) 1 (10%)	(10) 4 (40%)
<b>HEMATOPOIETIC SYSTEM</b>						
Bone Marrow Hemorrhage	(10)	(0)	(0)	(10)	(10)	(10) 2 (20%)
Lymph Node, Mandibular Hyperplasia, Lymphoid Hyperplasia, Plasma Cell Hemorrhage	(10) 1 (10%) 1 (10%)	(0)	(0)	(10) 1 (10%)	(10)	(10)
Lymph Node, Mesenteric Necrosis	(10) 1 (10%)	(0)	(0)	(10)	(10)	(10)
Spleen Lymphoid Follicle, Depletion Cellular	(10)	(10)	(10)	(10)	(10)	(10) 1 (10%)
Thymus Necrosis Hemorrhage Atrophy	(10)	(10)	(10)	(10)	(10) 2 (20%) 2 (20%) 2 (20%)	(10) 3 (30%)
<b>INTEGUMENTARY SYSTEM</b>						
Skin Epidermis, Skin, Site Of Application, Hyperplasia	(10)	(10) 5 (50%)	(10) 7 (70%)	(10) 10 (100%)	(10) 10 (100%)	(10) 3 (30%)
Epidermis, Skin, Site Of Application, Necrosis, Focal						9 (90%)
Skin, Site Of Application, Inflammation, Chronic Active				1 (10%)	7 (70%)	10 (100%)
<b>MUSCULOSKELETAL SYSTEM</b>						
None						
<b>NERVOUS SYSTEM</b>						

TDMS No. 93020 - 03  
 Test Type: 90-DAY  
 Route: SKIN APPLICATION  
 Species/Strain: RATS/F 344

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)  
 DIISOPROPYLCARBODIIMIDE  
 CAS Number: 693-13-0  
 Pathologist: BIERLEY, B. - STEDHAM, M. - SHANAHAN, P.

Date Report Requested: 08/08/2005  
 Time Report Requested: 08:53:32  
 First Dose M/F: 09/06/94 / 09/07/94  
 Lab: MBA

FISCHER 344 RATS MALE	0 MG/KG	10 MG/KG	20 MG/KG	40 MG/KG	80 MG/KG	160 MG/KG
Brain	(10)	(10)	(10)	(10)	(10)	(10)
Edema, Focal					5 (50%)	1 (10%)
Hemorrhage					1 (10%)	4 (40%)
Congestion						1 (10%)
Arteriole, Necrosis, Fibrinoid						1 (10%)
Neuron, Necrosis					8 (80%)	
<b>RESPIRATORY SYSTEM</b>						
Lung	(10)	(0)	(0)	(10)	(10)	(10)
Congestion					5 (50%)	8 (80%)
Hemorrhage					1 (10%)	
Alveolus, Infiltration Cellular, Histiocyte	1 (10%)				1 (10%)	
Interstitial, Inflammation, Chronic Active	1 (10%)				1 (10%)	
Perivascular, Infiltration Cellular, Lymphocyte	3 (30%)			6 (60%)	1 (10%)	
Nose	(10)	(0)	(0)	(10)	(10)	(10)
Respiratory Epithelium, Inflammation, Chronic Active	3 (30%)			1 (10%)	1 (10%)	5 (50%)
Respiratory Epithelium, Metaplasia, Squamous						3 (30%)
Squamous Epithelium, Inflammation, Chronic				1 (10%)		
Squamous Epithelium, Inflammation, Chronic Active						1 (10%)
<b>SPECIAL SENSES SYSTEM</b>						
Eye	(0)	(0)	(0)	(0)	(1)	(0)
Cornea, Bilateral, Degeneration, Focal					1 (100%)	
<b>URINARY SYSTEM</b>						
Kidney	(10)	(0)	(0)	(10)	(10)	(10)
Nephropathy	5 (50%)			2 (20%)		

**TDMS No.** 93020 - 03  
**Test Type:** 90-DAY  
**Route:** SKIN APPLICATION  
**Species/Strain:** RATS/F 344

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**  
DIISOPROPYLCARBODIIMIDE  
**CAS Number:** 693-13-0  
**Pathologist:** BIERLEY, B. - STEDHAM, M. - SHANAHAN, P.

**Date Report Requested:** 08/08/2005  
**Time Report Requested:** 08:53:32  
**First Dose M/F:** 09/06/94 / 09/07/94  
**Lab:** MBA

---

<b>FISCHER 344 RATS MALE</b>	<b>0 MG/KG</b>	<b>10 MG/KG</b>	<b>20 MG/KG</b>	<b>40 MG/KG</b>	<b>80 MG/KG</b>	<b>160 MG/KG</b>
------------------------------	----------------	-----------------	-----------------	-----------------	-----------------	------------------

---

\*\*\* END OF MALE \*\*\*

TDMS No. 93020 - 03  
 Test Type: 90-DAY  
 Route: SKIN APPLICATION  
 Species/Strain: RATS/F 344

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)  
 DIISOPROPYLCARBODIIMIDE  
 CAS Number: 693-13-0  
 Pathologist: BIERLEY, B. - STEDHAM, M. - SHANAHAN, P.

Date Report Requested: 08/08/2005  
 Time Report Requested: 08:53:32  
 First Dose M/F: 09/06/94 / 09/07/94  
 Lab: MBA

FISCHER 344 RATS FEMALE	0 MG/KG	10 MG/KG	20 MG/KG	40 MG/KG	80 MG/KG	160 MG/KG
<b>Disposition Summary</b>						
Animals Initially in Study	10	10	10	10	10	10
Early Deaths						
Moribund Sacrifice					10	10
Survivors						
Accidentally Killed	1					
Terminal Sacrifice	9	10	10	10		
Animals Examined Microscopically	10	10	10	10	10	10
<b>ALIMENTARY SYSTEM</b>						
Liver	(10)	(0)	(0)	(10)	(10)	(10)
Congestion					1 (10%)	
Centrilobular, Congestion						2 (20%)
Mesentery	(0)	(0)	(0)	(1)	(0)	(0)
Fat, Necrosis				1 (100%)		
Pancreas	(10)	(0)	(0)	(10)	(10)	(10)
Acinus, Cytoplasmic Alteration, Focal	1 (10%)					
<b>CARDIOVASCULAR SYSTEM</b>						
Heart	(10)	(10)	(10)	(10)	(10)	(10)
Cardiomyopathy			1 (10%)	2 (20%)	2 (20%)	
<b>ENDOCRINE SYSTEM</b>						
Adrenal Cortex	(10)	(0)	(0)	(10)	(10)	(10)
Hypertrophy, Focal	1 (10%)					
<b>GENERAL BODY SYSTEM</b>						
None						
<b>GENITAL SYSTEM</b>						
Clitoral Gland	(8)	(0)	(0)	(6)	(10)	(10)

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 93020 - 03  
 Test Type: 90-DAY  
 Route: SKIN APPLICATION  
 Species/Strain: RATS/F 344

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)  
 DIISOPROPYLCARBODIIMIDE  
 CAS Number: 693-13-0  
 Pathologist: BIERLEY, B. - STEDHAM, M. - SHANAHAN, P.

Date Report Requested: 08/08/2005  
 Time Report Requested: 08:53:32  
 First Dose M/F: 09/06/94 / 09/07/94  
 Lab: MBA

FISCHER 344 RATS FEMALE	0 MG/KG	10 MG/KG	20 MG/KG	40 MG/KG	80 MG/KG	160 MG/KG
Inflammation, Chronic Active				1 (17%)	2 (20%)	1 (10%)
Ovary	(10)	(0)	(0)	(10)	(10)	(10)
Cyst				1 (10%)		
Uterus	(10)	(1)	(5)	(10)	(10)	(10)
Hydrometra			5 (100%)	4 (40%)		1 (10%)
<b>HEMATOPOIETIC SYSTEM</b>						
Bone Marrow	(10)	(0)	(0)	(10)	(10)	(10)
Hyperplasia, Focal, Lymphoid				1 (10%)		
Hyperplasia, Focal, Histiocytic				2 (20%)		
Hemorrhage					1 (10%)	2 (20%)
Atrophy					1 (10%)	
Lymph Node, Mandibular	(10)	(0)	(0)	(9)	(9)	(10)
Hemorrhage					1 (11%)	
Hyperplasia, Lymphoid					1 (11%)	2 (20%)
Lymph Node, Mesenteric	(10)	(0)	(0)	(10)	(10)	(10)
Hyperplasia, Histiocytic	1 (10%)			1 (10%)		
Hyperplasia, Lymphoid				1 (10%)		
Thymus	(10)	(10)	(10)	(10)	(10)	(10)
Atrophy					4 (40%)	1 (10%)
<b>INTEGUMENTARY SYSTEM</b>						
Skin	(10)	(10)	(10)	(10)	(10)	(10)
Epidermis, Skin, Site Of Application, Hyperplasia	1 (10%)	2 (20%)	3 (30%)	5 (50%)	10 (100%)	10 (100%)
Epidermis, Skin, Site Of Application, Necrosis, Focal						10 (100%)
Skin, Site Of Application, Inflammation, Chronic Active					7 (70%)	10 (100%)
<b>MUSCULOSKELETAL SYSTEM</b>						
None						
<b>NERVOUS SYSTEM</b>						
Brain	(10)	(10)	(10)	(10)	(10)	(10)

TDMS No. 93020 - 03  
 Test Type: 90-DAY  
 Route: SKIN APPLICATION  
 Species/Strain: RATS/F 344

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)  
 DIISOPROPYLCARBODIIMIDE  
 CAS Number: 693-13-0  
 Pathologist: BIERLEY, B. - STEDHAM, M. - SHANAHAN, P.

Date Report Requested: 08/08/2005  
 Time Report Requested: 08:53:32  
 First Dose M/F: 09/06/94 / 09/07/94  
 Lab: MBA

FISCHER 344 RATS FEMALE	0 MG/KG	10 MG/KG	20 MG/KG	40 MG/KG	80 MG/KG	160 MG/KG
Edema, Focal					5 (50%)	2 (20%)
Hemorrhage					5 (50%)	6 (60%)
Arteriole, Necrosis, Fibrinoid					1 (10%)	
Neuron, Necrosis					8 (80%)	2 (20%)
<b>RESPIRATORY SYSTEM</b>						
Lung	(10)	(0)	(0)	(10)	(10)	(10)
Congestion					5 (50%)	8 (80%)
Hemorrhage					1 (10%)	
Interstitial, Inflammation, Chronic Active	1 (10%)			3 (30%)		
Perivascular, Infiltration Cellular, Lymphocyte	4 (40%)			5 (50%)	4 (40%)	
Nose	(10)	(0)	(0)	(10)	(10)	(10)
Olfactory Epithelium, Atrophy	1 (10%)					
Olfactory Epithelium, Inflammation, Chronic Active				1 (10%)		
Respiratory Epithelium, Atrophy					1 (10%)	
Respiratory Epithelium, Inflammation, Chronic Active	1 (10%)					2 (20%)
Squamous Epithelium, Inflammation, Chronic Active					1 (10%)	
<b>SPECIAL SENSES SYSTEM</b>						
None						
<b>URINARY SYSTEM</b>						
Kidney	(10)	(0)	(0)	(10)	(10)	(10)
Congestion					1 (10%)	1 (10%)
Medulla, Mineralization	5 (50%)			6 (60%)	10 (100%)	3 (30%)
Urinary Bladder	(10)	(0)	(0)	(10)	(10)	(10)
Serosa, Mineralization				1 (10%)		

\*\*\* END OF REPORT \*\*\*